查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1572093

注意力不足過動症市場：按治療方法、患者類型和應用分類 - 全球預測 2025-2030

Attention Deficit Hyperactivity Disorder Market by Therapies (Pharmacotherapy, Psychotherapy), Patient Type (In-Patients, Out-Patients), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

注意力不足過動症市場2023年估值為149.9億美元，預計2024年將達到156.1億美元，複合年成長率為4.18%，到2030年將達到199.8億美元，預計將達到1000萬美元。

注意力不足過動症(ADHD) 是一種神經發育障礙，其特徵是注意力不集中、過動和衝動，影響兒童的教育表現和成人的職業生產力。 ADHD 市場分析的範圍包括藥物、行為療法和數位療法，其促進因素包括意識的提高、診斷程序的改善和盛行率的增加。 ADHD治療的需要和應用是基於改善患者的生活品質，這對家庭、教育機構和職場都具有重要意義。最終用途範圍包括兒科和成人患者、教育機構、醫療保健提供者、實驗室等。該市場的促進因素包括不斷增加的發病率、複雜的治療選擇以及社會對心理健康需求的認知不斷增強。關鍵的成長要素包括遠端醫療服務、個人化醫療和政府醫療保健舉措等技術進步。機會包括擴大接受數位療法和非侵入性神經反饋療法等新型療法。鼓勵市場相關人員投資這些新技術的研發，擴大與醫療機構和學術機構的合作關係，並推廣產品。儘管成長軌跡充滿活力，但挑戰仍然存在，包括污名化、地區不同的診斷標準以及高昂的治療成本。進一步的障礙包括新藥認證的監管障礙以及擴大保險覆蓋範圍的複雜性。需要開拓創新領域，包括人工智慧驅動的診斷工具、具有成本效益的治療提供模式以及消除恥辱感的宣傳活動。 ADHD 市場本質上是動態的，由醫療保健、技術和社會文化趨勢的相互作用形成。透過投資以患者為中心的創新和策略夥伴關係關係而定位於這些領域融合的公司可能會在這一領域取得成功。為了有效捕捉市場潛力，企業必須保持適應能力，以快速回應不斷變化的監管標準和消費者期望。

主要市場統計
基準年[2023] 149.9億美元
預測年份 [2024] 156.1億美元
預測年份 [2030] 199.8億美元
複合年成長率（%） 4.18%

市場動態：針對快速發展的注意力不足過動症市場揭示的關鍵市場洞察

供需的動態交互作用正在改變注意力不足過動症市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球兒童和成人注意力不足過動症的盛行率不斷上升
    • 早期發現注意力不足過動症的診斷工具和技術的進展
    • 提高家長和教育工作者對注意力不足過動症的認知和教育舉措
    • 注意力不足過動症市場創新治療方法的研發活動迅速增加
  • 市場限制因素
    • 由於缺乏具有多動症專業知識的合格心理健康專業人員，造成診斷和治療的延遲和錯誤
  • 市場機會
    • 針對不同年齡層過動症患者症狀特異性緩解的創新藥物製劑
    • 客製化的教育計畫和工具旨在增強過動症兒童的學習體驗
    • 針對患有多動症的成年人的職場適應解決方案著重於提高生產力和心理健康
  • 市場挑戰
    • ADHD 診斷和治療的高昂費用和有限的保險覆蓋範圍降低了患者的可及性。

波特的五力：駕馭注意力不足過動症市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解注意力不足過動症市場的外在影響

外在宏觀環境因素在塑造注意力不足過動症市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解注意力不足過動症市場的競爭格局

注意力不足過動症市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 在注意力不足過動症市場的定位矩陣供應商績效評估

FPNV 定位矩陣是評估注意力不足過動症市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製注意力不足過動症市場的成功之路

對注意力不足過動症市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球兒童和成人注意力不足過動症盛行率上升
      • 早期發現注意力不足過動症的診斷工具和技術的進展
      • 家長和教育工作者對注意力不足過動症的認知和教育工作正在不斷增加。
      • 注意力不足過動症市場創新治療方法的研發活動激增
    • 抑制因素
      • 缺乏具有多動症專業知識的合格心理健康專業人員會導致診斷和治療的延遲或治療的不正確。
    • 機會
      • 針對不同年齡層 ADHD 症狀特異性緩解的創新藥物配方
      • 旨在改善過動症兒童的學習體驗的客製化教育計劃和工具
      • 針對成人的過動症職場調整解決方案，專注於提高生產力和心理健康
    • 任務
      • ADHD 診斷和治療的高成本和有限的保險範圍限制了患者的取得。
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章注意力不足過動症的市場療法

  • 藥物治療
    • 無刺激性
    • 興奮劑
  • 心理治療
    • 行為療法
    • 認知行為療法
    • 家庭治療
    • 社交技能訓練

第 7 章依病患類型分類的注意力不足過動症市場

  • 住院病人
  • 門診病人

第8章注意力不足過動症市場：依應用分類

  • 注意力缺陷障礙
  • 過動症

第9章美洲注意力不足過動症市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區注意力不足過動症市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲注意力不足過動症市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0088

The Attention Deficit Hyperactivity Disorder Market was valued at USD 14.99 billion in 2023, expected to reach USD 15.61 billion in 2024, and is projected to grow at a CAGR of 4.18%, to USD 19.98 billion by 2030.

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity, impacting children's educational performance and adults' professional productivity. The scope of market analysis for ADHD encompasses pharmaceuticals, behavioral therapy, and digital therapies, driven by rising awareness, improved diagnostic procedures, and increased prevalence. The necessity and application of ADHD treatments are based on enhancing patients' life quality, making them crucial for households, educational institutions, and workplaces. The end-use scope includes pediatric and adult patients, educational settings, healthcare providers, and research labs. The market is propelled by increasing incidence rates, sophisticated treatment options, and heightened societal recognition of mental health needs. Key growth influencers include technological advancements like telehealth services, personalized medicine, and government healthcare initiatives. Opportunistically, the evolving acceptance of novel treatments like digital therapeutics and non-invasive neurofeedback therapies presents unexplored opportunities. Market players are recommended to invest in R&D for these emerging technologies and expand collaborations with healthcare facilities and academic institutions for broader product dissemination. Despite the vibrant growth trajectory, challenges such as stigmatization, varied diagnosis standards across regions, and high treatment costs persist. Additionally, regulatory hurdles for new drug approvals and the complexity of gaining widespread insurance coverage pose barriers. Innovation areas ripe for exploration include AI-driven diagnostic tools, cost-effective treatment delivery models, and awareness campaigns to battle stigma. The ADHD market is inherently dynamic, shaped by intersecting healthcare, technological, and sociocultural trends. Businesses positioning themselves at the convergence of these domains with investment in patient-centered innovations and strategic partnerships stand the best chance of thriving in this sector. Companies should maintain adaptability to swiftly align with evolving regulatory standards and consumer expectations to capture market potential effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 14.99 billion
Estimated Year [2024] USD 15.61 billion
Forecast Year [2030] USD 19.98 billion
CAGR (%) 4.18%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Attention Deficit Hyperactivity Disorder Market

The Attention Deficit Hyperactivity Disorder Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of attention deficit hyperactivity disorder among children and adults worldwide
    • Advancements in diagnostic tools and techniques for early detection of attention deficit hyperactivity disorder
    • Growing awareness and educational initiatives about attention deficit hyperactivity disorder among parents and educators
    • Surge in research and development activities for innovative treatment options in attention deficit hyperactivity disorder market
  • Market Restraints
    • Lack of qualified mental health professionals with expertise in ADHD leading to delayed or incorrect diagnosis and treatment
  • Market Opportunities
    • Innovative pharmaceutical formulations targeting symptom-specific relief for different age groups with ADHD
    • Customized educational programs and tools designed to enhance learning experiences for children with ADHD
    • Workplace accommodation solutions for adults with ADHD focusing on productivity and mental health improvement
  • Market Challenges
    • High cost of ADHD diagnosis and treatment combined with limited insurance coverage reduces accessibility for patients

Porter's Five Forces: A Strategic Tool for Navigating the Attention Deficit Hyperactivity Disorder Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Attention Deficit Hyperactivity Disorder Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Attention Deficit Hyperactivity Disorder Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Attention Deficit Hyperactivity Disorder Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Attention Deficit Hyperactivity Disorder Market

A detailed market share analysis in the Attention Deficit Hyperactivity Disorder Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Attention Deficit Hyperactivity Disorder Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Attention Deficit Hyperactivity Disorder Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Attention Deficit Hyperactivity Disorder Market

A strategic analysis of the Attention Deficit Hyperactivity Disorder Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Attention Deficit Hyperactivity Disorder Market, highlighting leading vendors and their innovative profiles. These include Akili Interactive Labs, Inc., Austedo Pharmaceuticals, Cingulate Therapeutics, LLC, Eli Lilly and Company, Ironshore Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., KemPharm, Inc., Medice Arzneimittel Putter GmbH & Co. KG, Neos Therapeutics, Inc., NeuroSigma, Inc., NLS Pharmaceutics AG, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Shire Plc, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Attention Deficit Hyperactivity Disorder Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapies, market is studied across Pharmacotherapy and Psychotherapy. The Pharmacotherapy is further studied across Non-Stimulants and Stimulants. The Psychotherapy is further studied across Behavioral Therapy, Cognitive Behavioral Therapy, Family Therapy, and Social Skills Training.
  • Based on Patient Type, market is studied across In-Patients and Out-Patients.
  • Based on Application, market is studied across Attention Deficit Disorder and Hyperactive Disorder.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of attention deficit hyperactivity disorder among children and adults worldwide
      • 5.1.1.2. Advancements in diagnostic tools and techniques for early detection of attention deficit hyperactivity disorder
      • 5.1.1.3. Growing awareness and educational initiatives about attention deficit hyperactivity disorder among parents and educators
      • 5.1.1.4. Surge in research and development activities for innovative treatment options in attention deficit hyperactivity disorder market
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of qualified mental health professionals with expertise in ADHD leading to delayed or incorrect diagnosis and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative pharmaceutical formulations targeting symptom-specific relief for different age groups with ADHD
      • 5.1.3.2. Customized educational programs and tools designed to enhance learning experiences for children with ADHD
      • 5.1.3.3. Workplace accommodation solutions for adults with ADHD focusing on productivity and mental health improvement
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of ADHD diagnosis and treatment combined with limited insurance coverage reduces accessibility for patients
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Attention Deficit Hyperactivity Disorder Market, by Therapies

  • 6.1. Introduction
  • 6.2. Pharmacotherapy
    • 6.2.1. Non-Stimulants
    • 6.2.2. Stimulants
  • 6.3. Psychotherapy
    • 6.3.1. Behavioral Therapy
    • 6.3.2. Cognitive Behavioral Therapy
    • 6.3.3. Family Therapy
    • 6.3.4. Social Skills Training

7. Attention Deficit Hyperactivity Disorder Market, by Patient Type

  • 7.1. Introduction
  • 7.2. In-Patients
  • 7.3. Out-Patients

8. Attention Deficit Hyperactivity Disorder Market, by Application

  • 8.1. Introduction
  • 8.2. Attention Deficit Disorder
  • 8.3. Hyperactive Disorder

9. Americas Attention Deficit Hyperactivity Disorder Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Attention Deficit Hyperactivity Disorder Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Attention Deficit Hyperactivity Disorder Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akili Interactive Labs, Inc.
  • 2. Austedo Pharmaceuticals
  • 3. Cingulate Therapeutics, LLC
  • 4. Eli Lilly and Company
  • 5. Ironshore Pharmaceuticals Inc.
  • 6. Janssen Pharmaceuticals, Inc.
  • 7. KemPharm, Inc.
  • 8. Medice Arzneimittel Putter GmbH & Co. KG
  • 9. Neos Therapeutics, Inc.
  • 10. NeuroSigma, Inc.
  • 11. NLS Pharmaceutics AG
  • 12. Novartis AG
  • 13. Otsuka Pharmaceutical Co., Ltd.
  • 14. Pfizer Inc.
  • 15. Shire Plc
  • 16. Sunovion Pharmaceuticals Inc.
  • 17. Supernus Pharmaceuticals, Inc.
  • 18. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET RESEARCH PROCESS
  • FIGURE 2. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET DYNAMICS
  • TABLE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON-STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY SOCIAL SKILLS TRAINING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY IN-PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY OUT-PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ATTENTION DEFICIT DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HYPERACTIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 234. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023